Ameriprise Financial Inc. Reduces Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Ameriprise Financial Inc. reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 45.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 90,627 shares of the specialty pharmaceutical company's stock after selling 75,390 shares during the period. Ameriprise Financial Inc. owned about 0.28% of Collegium Pharmaceutical worth $2,596,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. New Age Alpha Advisors LLC bought a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $40,000. KBC Group NV increased its holdings in Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after purchasing an additional 982 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after purchasing an additional 316 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after purchasing an additional 642 shares in the last quarter. Finally, Aigen Investment Management LP bought a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $230,000.

Analysts Set New Price Targets

A number of analysts have commented on the company. Wall Street Zen lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $43.80.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 1,949 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the sale, the chief financial officer now owns 177,195 shares in the company, valued at $5,315,850. This represents a 1.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $28.50, for a total value of $742,909.50. Following the sale, the executive vice president now owns 108,137 shares in the company, valued at approximately $3,081,904.50. This represents a 19.42% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 81,693 shares of company stock worth $2,334,994. Insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock traded up $0.17 during trading on Monday, hitting $29.31. The company's stock had a trading volume of 247,918 shares, compared to its average volume of 421,877. The company has a market cap of $941.79 million, a PE ratio of 12.63 and a beta of 0.63. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The business has a fifty day moving average of $28.00 and a 200-day moving average of $29.60. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $177.76 million during the quarter, compared to analysts' expectations of $174.96 million. During the same quarter in the previous year, the company posted $1.45 EPS. Collegium Pharmaceutical's revenue for the quarter was up 22.7% on a year-over-year basis. As a group, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.